百家乐怎么玩-澳门百家乐官网娱乐城网址_网上百家乐是不是真的_全讯网888 (中国)·官方网站

First dual stem cell therapy brings new hope for cardiac repair

Donna Wong

 

190910-1_research_0.jpg
Dr Ban Ki-won (middle) and his research team at CityU.

 

A research team featuring an expert from City University of Hong Kong (CityU) has developed a novel dual approach for the first time for concurrently rejuvenating both the cardiac muscle and vasculature of the heart by utilising two types of stem cells. The results give hope for a new treatment for repairing myocardial infarction (MI) heart. 

  190910-2_research_1.jpg
These are the specimens of rats’ hearts used in the research.

 

Dr Ban Ki-won, Assistant Professor of the Department of Biomedical Sciences and his research team, including researchers from Konkuk University, The Catholic University of Korea, Pohang University of Science and Technology and T&R Biofab in South Korea, have conducted the first study of two distinct stem cell effects for cardiac repair. The two major types of stem cells employed are human bone marrow derived mesenchymal stem cells (hMSCs) and cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs). The research findings have been published in Nature Communications in a paper titled “Dual stem cell therapy synergistically improves cardiac function and vascular regeneration following myocardial infarction”. 

“Both cardiac muscles and vasculatures are severely damaged following MI, and so the therapeutic strategies should focus on comprehensive repair of both at the same time. But the current strategies only focus on either one,” Dr Ban said. 

Dr Ban said that, with limited therapeutic options for severe MI and advanced heart failure, a heart transplant was the last resort. However, such an operation is very risky, costly and subject to limited supply of suitable donors. Therefore, stem cell-based therapy has emerged as a promising therapeutic option.

190910-3_research_4.jpg
Representative immunostaining images showing hiPSC-CM-GFP (green) and MYH6/7 gene (red) when hiPSC-CMs were injected in MI hearts.

 

In the study, the hiPSC-CMs were injected directly into the border zone of the rat's heart, while the hMSCs-loaded patch was implanted on top of the infarct area, like a bandage. The results showed that this dual approach led to a significant improvement of cardiac function and an enhancement of vessel formation on a MI heart. 

“We believe this novel dual approach can potentially provide translational and clinical benefit to the field of cardiac regeneration. Based on the same principle, the protocol may also be utilised for repairing other organs including the brain, liver and pancreas in which multiple types of stem cells co-exist,” Dr Ban added. 

The research team is working on follow-up studies in larger animal models such as pigs. The patent application for this research result has been submitted.

The first co-authors of the paper are Dr Park Soon-jung from Konkuk University School of Medicine, Dr Kim Ri-youn and PhD student Lee Sung-hun from CityU and PhD student Park Bong-woo from The Catholic University of Korea.

 

 

YOU MAY BE INTERESTED

Contact Information

Communications and Institutional Research Office

Back to top
百家乐官网庄闲概率| 新加坡百家乐官网的玩法技巧和规则| 宝都棋牌下载| 百家乐椅子| 锦州市| 百家乐平台哪个好本站所有数据都是网友推荐及提供 | 尊龙百家乐官网娱乐| 大发888 充值| 百家乐看不到视频| A8百家乐官网现金网| 24山认龙立向| 杰克棋牌是真的吗| 博九百家乐游戏| 澳门百家乐官网投注法| 百家乐高手论| 百家乐官网书包| 百家乐顶路| 菲律宾百家乐官网开户| bet365是否合法| 成都百家乐牌具| 免费百家乐官网倍投软件| 百家乐官网现金网排名| 恒丰百家乐的玩法技巧和规则 | 棋牌平台| 百家乐长t恤| 单耳房做生意的风水| 永盈会娱乐场官网| 大众百家乐官网的玩法技巧和规则| 鄂尔多斯市| 永盈会娱乐场官网| 百家乐半圆桌| 阴宅风水24山分金| 玩百家乐官网犯法| 网页百家乐官网| 百家乐真钱游戏| 澳门百家乐网络游戏信誉怎么样 | 百家乐官网做庄家必赢诀窍| 百家乐人生信条漫谈| 百家乐官网双龙出海注码法| 龙山县| 大丰收娱乐城开户|